|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100050308 |
|
最近更新日期: Date of Last Refreshed on: |
2022-03-28 17:55:11 |
|
注册时间: Date of Registration: |
2021-08-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
阴茎勃起硬度值对前列腺癌根治术后阴茎康复的预测作用 |
|
Public title: |
Predictive effect of penile erectile hardness value on penile recovery after radical resection of prostate cancer |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
阴茎勃起硬度值对前列腺癌根治术后阴茎康复的预测作用 |
|
Scientific title: |
Predictive effect of penile erectile hardness value on penile recovery after radical resection of prostate cancer |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邢召全 |
研究负责人: |
邢召全 |
|
Applicant: |
Xing Zhaoquan |
Study leader: |
Xing Zhaoquan |
|
申请注册联系人电话: Applicant telephone: |
+86 18560083901 |
研究负责人电话:
Study leader's |
+86 18560083901 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
sdql2011@126.com |
研究负责人电子邮件: Study leader's E-mail: |
sdql2011@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省济南市历下区文化西路107号 |
研究负责人通讯地址: |
山东省济南市历下区文化西路107号 |
|
Applicant address: |
107 Wenhua Road West, Lixia District, Ji'nan, Shandong |
Study leader's address: |
107 Wenhua Road West, Lixia District, Ji'nan, Shandong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东大学齐鲁医院 |
||
|
Applicant's institution: |
Qilu Hospital of Shandong University |
||
|
研究负责人所在单位: |
山东大学齐鲁医院 |
||
|
Affiliation of the Leader: |
Qilu Hospital of Shandong University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(科)伦审第2020(061)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山东大学齐鲁医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Qilu Hospital of Shandong University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-12-25 00:00:00 | ||
|
伦理委员会联系人: |
傅昌 |
||
|
Contact Name of the ethic committee: |
Fu Chang |
||
|
伦理委员会联系地址: |
山东省济南市历下区文化西路107号 |
||
|
Contact Address of the ethic committee: |
107 Wenhua Road West, Lixia District, Ji'nan, Shandong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
山东大学齐鲁医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Qilu Hospital of Shandong University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省济南市历下区文化西路107号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
107 Wenhua Road West, Lixia District, Ji'nan, Shandong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东大学临床研究项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical Research Project of Shandong University |
||||||||||||||||||||||
|
研究疾病: |
前列腺癌 |
||||||||||||||||||||||
|
Target disease: |
Prostate cancer |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
建立具有预测价值的术前夜间勃起监测(NPTR)基础硬度值联合其他临床指标的前列腺癌根治术(RP)患者术后6个月勃起功能障碍的精准预测模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
To establish an accurate predictive model of erectile dysfunction 6 months after radical prostate cancer surgery (RP) based on preoperative nocturnal erectile monitoring (NPTR) basic hardness value combined with other clinical indicators. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①患者年龄在70岁以下,签署知情同意;②研究对象为经临床病理确诊为前列腺癌的患者,参照美国抗癌协会(AJCC)2002年的标准,并接受标准的Walsh双侧神经保留手术,所使用的麻醉药物、方式、时间等均固定;③术者固定为有经验的专科医生(手术例数>300台),手术方式为固定术式,手术时间控制在2小时以内,手术地点固定,出血量<50ml,不损伤其他器官组织;④同意接受RP术后阴茎康复治疗,服用药物剂量及时间固定; |
||||||||||||||||||||||
|
Inclusion criteria |
① The patient is under the age of 70 years old and signed the informed consent;② The subjects were patients with clinically pathologically diagnosed prostate cancer, who received standard Walsh bilateral nerve spreservation surgery according to the standards of the American Anti-Cancer Society (AJCC) in 2002, and the anesthetic drugs, methods and time were fixed;③ The surgeons were fixed as experienced specialists (the number of surgical cases was > 300), the operation method was fixed operation, the operation time was controlled within 2 hours, the operation site was fixed, and the amount of blood loss was <50ml, no damage to other organs and tissues;(4) agree to receive penile rehabilitation treatment after RP operation, and take drug dosage and time fixed;⑤ No serious complications and/or other major chronic diseases were found after surgery. |
||||||||||||||||||||||
|
排除标准: |
③术后严重并发症,如尿失禁、严重血尿、感染;④术后短期内肿瘤复发转移;⑤无性生活需求,无糖尿病、严重肥胖、脂肪肝、痛风以及伴有其他严重疾病如恶性肿瘤、慢性肝肾疾病等;⑥合并慢性疾病,如糖尿病、其他恶性肿瘤、肝肾功能不全及严重心血管疾病等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) The patient is more than 70 years old, or have not signed the informed consent;② Bilateral nerve sparing was not performed intraoperatively;③ Serious postoperative complications, such as urinary incontinence, severe hematuria, infection;(4) Tumor recurrence and metastasis in a short period after surgery;(5) No need for sexual life or no postoperative penile rehabilitation treatment; no diabetes, severe obesity, fatty liver, gout, or other serious diseases such as malignant tumor, chronic liver and kidney disease;(6) Complicated with chronic diseases, such as diabetes, other malignant tumors, liver and kidney insufficiency and serious cardiovascular diseases. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-09-01 00:00:00至 To 2023-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-09-01 00:00:00 至 To 2022-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
收集来源山东大学齐鲁医院泌尿外科2021年1月-2022年6月连续入组的前列腺癌住院手术患者,开展前瞻性队列研究和巢式病例对照研究。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
a prospective cohort study and a nested case-control study were conducted among consecutive patients with prostate cancer from January 2021 to June 2022 in the Department of Urology, Qilu Hospital, Shandong University |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023年公布,采用第三方网络平台 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Announced in 2023, the third-party network platform is adopted |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |